Everolimus‐facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2‐year results from the subgroup analysis of the TRANSFORM study

OBJECTIVE: We analyzed the efficacy and safety of an everolimus with reduced‐exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolic acid with standard‐exposure CNI (MPA+sCNI) regimen in Asian patients from the TRANSFORM study. METHODS: In this 24‐month, open‐label study, de novo kidney transp...

Descripción completa

Detalles Bibliográficos
Autores principales: Watarai, Yoshihiko, Danguilan, Romina, Casasola, Concesa, Chang, Shen‐Shin, Ruangkanchanasetr, Prajej, Kee, Terence, Wong, Hin Seng, Kenmochi, Takashi, Amante, Angel Joaquin, Shu, Kuo‐Hsiung, Ingsathit, Atiporn, Bernhardt, Peter, Hernandez‐Gutierrez, Maria Pilar, Han, Duck Jong, Kim, Myoung Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255374/
https://www.ncbi.nlm.nih.gov/pubmed/34216395
http://dx.doi.org/10.1111/ctr.14415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255374/
https://www.ncbi.nlm.nih.gov/pubmed/34216395
http://dx.doi.org/10.1111/ctr.14415

Ejemplares similares